Real-time Stock quotes, portfolio, LIVE TV and more.
Jun 06, 2012, 02.08 PM IST
DRREDDYSLABORATORIES-BRIEF:Merck KGaA, Dr. Reddy's to cooperate on biosimilars
FRANKFURT (Reuters) - German pharmaceutical company Merck KGaA and India's Dr. Reddy's Laboratories Ltd
The deal is the latest example of drug companies jumping into a new space that is opening up as patents on biotech medicines expire.
"Sharing know-how, risks and rewards is the right approach to enter the emergent biosimilars market and will be a win-win for both parties," Merck executive board member Stefan Oschmann said in a statement on Wednesday.
Under the agreement, Merck and Dr. Reddy's will co-develop molecules and Dr. Reddy's will lead early product development and testing.
Merck will manufacture the compounds and lead late-stage development. It will also handle commercialisation in large parts of the world and will pay Dr. Reddy's royalties.
(Reporting by Maria Sheahan)
May 22 2013, 13:11
- in MARKET OUTLOOK
May 22 2013, 10:44
- in Economy